Stockreport

MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

MediciNova, Inc.  (MNOV) 
Last medicinova, inc. earnings: 4/23 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: medicinova.com/investor-relations/media-archive
PDF LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Marke [Read more]